Late treatment study
et al., British Journal of Clinical Pharmacology, doi:10.1111/bcp.14482 (Peer Reviewed)
Clinical outcomes and adverse events in patients hospitalised with COVID‐19, treated with off‐label hydroxych loroquine and azithromycin
Retrospective 82 hospitalized patients HC Q/AZ, 52 SOC, not finding statistically significant differences. Confounding by indication. No attempt to adjust for confounders. HC Q/AZ patients were more severely ill with higher C‐reactive protein and fraction of inspired oxygen requirements at baseline.
Please send us corrections, updates, or comments.